Clinical Trial: NCT03728972
Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Memorial Sloan Kettering Cancer Center |
| Information Provided By: | Memorial Sloan Kettering Cancer Center |
| Last Update Posted: | 2026-10-21 |
Study Overview
Brief Summary
The purpose of this study is to test how well pembrolizumab shrinks Early-Stage NK/T-cell Lymphoma (ENKTL) in participants who have not yet received chemotherapy.
Official Title
Pilot Study of Pembrolizumab in Untreated Extranodal, NK/T Cell Lymphoma, Nasal Type
Conditions
NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis), NK/T-Cell Lymphoma of Nasopharynx (Diagnosis)
Intervention / Treatment
- Drug: Pembrolizumab
Other Study ID Numbers
- 18-393
Start Date (Actual)
2018-11-09
Primary Completion Date (Actual)
2025-06-15
Study Completion Date (Estimated)
2026-11
Enrollment (Actual)
19
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Memorial Sloan Kettering Cancer Center |
| Information Provided By: | Memorial Sloan Kettering Cancer Center |
| Last Update Posted: | 2026-10-21 |
Study Overview
Brief Summary
The purpose of this study is to test how well pembrolizumab shrinks Early-Stage NK/T-cell Lymphoma (ENKTL) in participants who have not yet received chemotherapy.
Official Title
Pilot Study of Pembrolizumab in Untreated Extranodal, NK/T Cell Lymphoma, Nasal Type
Conditions
NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis), NK/T-Cell Lymphoma of Nasopharynx (Diagnosis)
Intervention / Treatment
- Drug: Pembrolizumab
Other Study ID Numbers
- 18-393
Start Date (Actual)
2018-11-09
Primary Completion Date (Actual)
2025-06-15
Study Completion Date (Estimated)
2026-11
Enrollment (Actual)
19
Study Type
Interventional
Phase
Phase 2